NZ553127A - L-lactic, saccharin, cinnamic, salicyclic, benzenesulphonic and naphthalene-1,5-disulphonic acid addition salts of lercanidipine - Google Patents
L-lactic, saccharin, cinnamic, salicyclic, benzenesulphonic and naphthalene-1,5-disulphonic acid addition salts of lercanidipineInfo
- Publication number
- NZ553127A NZ553127A NZ553127A NZ55312705A NZ553127A NZ 553127 A NZ553127 A NZ 553127A NZ 553127 A NZ553127 A NZ 553127A NZ 55312705 A NZ55312705 A NZ 55312705A NZ 553127 A NZ553127 A NZ 553127A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lercanidipine
- salt
- acid addition
- benzenesulphonic
- salicyclic
- Prior art date
Links
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical class COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 title abstract 9
- 229960004294 lercanidipine Drugs 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 title abstract 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 title abstract 2
- 229940081974 saccharin Drugs 0.000 title abstract 2
- 235000019204 saccharin Nutrition 0.000 title abstract 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 title abstract 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 title 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 title 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 title 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000000010 aprotic solvent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003586 protic polar solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60414904P | 2004-08-24 | 2004-08-24 | |
| PCT/EP2005/009043 WO2006021397A1 (en) | 2004-08-24 | 2005-08-22 | Lercanidipine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ553127A true NZ553127A (en) | 2009-07-31 |
Family
ID=35159792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ553127A NZ553127A (en) | 2004-08-24 | 2005-08-22 | L-lactic, saccharin, cinnamic, salicyclic, benzenesulphonic and naphthalene-1,5-disulphonic acid addition salts of lercanidipine |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7683179B2 (https=) |
| EP (1) | EP1799644B1 (https=) |
| JP (1) | JP2008510754A (https=) |
| KR (1) | KR20070045351A (https=) |
| CN (1) | CN101048379A (https=) |
| AR (1) | AR050467A1 (https=) |
| AU (1) | AU2005276619B2 (https=) |
| BR (1) | BRPI0514606A (https=) |
| CA (1) | CA2575078A1 (https=) |
| EA (1) | EA011773B1 (https=) |
| ES (1) | ES2462921T3 (https=) |
| IL (1) | IL180905A0 (https=) |
| MX (1) | MX2007002141A (https=) |
| NO (1) | NO20071515L (https=) |
| NZ (1) | NZ553127A (https=) |
| PE (1) | PE20060629A1 (https=) |
| TW (1) | TW200613275A (https=) |
| WO (1) | WO2006021397A1 (https=) |
| ZA (1) | ZA200702364B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100926247B1 (ko) * | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| AR052918A1 (es) * | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
| AR053023A1 (es) * | 2005-02-25 | 2007-04-18 | Recordati Ireland Ltd | Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| CA2654230C (en) | 2006-06-12 | 2012-09-11 | Novartis Ag | Process for making a lactate salt of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| WO2008040367A1 (en) * | 2006-08-01 | 2008-04-10 | Union Quimico-Farmaceutica S.A. | Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof |
| US20080175872A1 (en) * | 2006-09-28 | 2008-07-24 | Osmotica Corp. | Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid |
| ES2306595B1 (es) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| IN2009DN05509A (https=) * | 2007-03-14 | 2010-04-30 | Teva Pharma | |
| WO2009017813A1 (en) * | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
| WO2009070311A2 (en) | 2007-11-26 | 2009-06-04 | Teva Pharmaceutical Industries Ltd. | Crystal forms of o-desmethylvenlafaxine fumarate |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US20100105743A1 (en) * | 2008-08-01 | 2010-04-29 | Gopal Krishna | Pharmaceutical compositions and methods for stabilizing the same |
| PL2320740T3 (pl) * | 2008-08-01 | 2014-09-30 | The Medicines Co | Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| WO2011121452A2 (en) * | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| EP4524132A4 (en) * | 2022-05-10 | 2026-04-22 | Myrodia Therapeutics Co Ltd | 2-METHYL-2-THIAZOLINE SALT |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8403866D0 (en) | 1984-02-14 | 1984-03-21 | Recordati Chem Pharm | Diphenylalkylaminoalkyl esters |
| US5696139A (en) | 1995-05-12 | 1997-12-09 | Recordati S.A., Chemical And Pharmaceutical Company | Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure |
| IT1275532B (it) * | 1995-07-14 | 1997-08-07 | Recordati Chem Pharm | Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa |
| US5767136A (en) | 1995-05-12 | 1998-06-16 | Recordati, S.A. Chemical And Pharmaceutical Company | 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls |
| IT1301759B1 (it) * | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| US20030069285A1 (en) | 2001-08-06 | 2003-04-10 | Recordati Ireland Limited | Novel solvate and crystalline forms of lercanidipine hydrochloride |
| US6852737B2 (en) | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
| US6699892B2 (en) * | 2002-06-04 | 2004-03-02 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salt of amlodipine and method of preparing the same |
| JP2006504800A (ja) * | 2002-10-16 | 2006-02-09 | レコーダチ アイルランド リミテッド | リシノプリル／レルカニジピンの組み合わせ治療 |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
-
2005
- 2005-08-19 TW TW094128384A patent/TW200613275A/zh unknown
- 2005-08-22 CA CA002575078A patent/CA2575078A1/en not_active Abandoned
- 2005-08-22 AU AU2005276619A patent/AU2005276619B2/en not_active Ceased
- 2005-08-22 WO PCT/EP2005/009043 patent/WO2006021397A1/en not_active Ceased
- 2005-08-22 NZ NZ553127A patent/NZ553127A/xx not_active IP Right Cessation
- 2005-08-22 CN CNA2005800284676A patent/CN101048379A/zh active Pending
- 2005-08-22 JP JP2007528715A patent/JP2008510754A/ja not_active Abandoned
- 2005-08-22 PE PE2005000963A patent/PE20060629A1/es not_active Application Discontinuation
- 2005-08-22 AR ARP050103516A patent/AR050467A1/es not_active Application Discontinuation
- 2005-08-22 EA EA200700492A patent/EA011773B1/ru not_active IP Right Cessation
- 2005-08-22 ES ES05776228.8T patent/ES2462921T3/es not_active Expired - Lifetime
- 2005-08-22 MX MX2007002141A patent/MX2007002141A/es not_active Application Discontinuation
- 2005-08-22 EP EP05776228.8A patent/EP1799644B1/en not_active Expired - Lifetime
- 2005-08-22 BR BRPI0514606-2A patent/BRPI0514606A/pt not_active IP Right Cessation
- 2005-08-22 KR KR1020077006715A patent/KR20070045351A/ko not_active Withdrawn
- 2005-08-24 US US11/211,769 patent/US7683179B2/en not_active Expired - Fee Related
-
2007
- 2007-01-23 IL IL180905A patent/IL180905A0/en unknown
- 2007-03-22 ZA ZA200702364A patent/ZA200702364B/xx unknown
- 2007-03-23 NO NO20071515A patent/NO20071515L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL180905A0 (en) | 2007-07-04 |
| EA200700492A1 (ru) | 2007-08-31 |
| AU2005276619B2 (en) | 2009-04-30 |
| KR20070045351A (ko) | 2007-05-02 |
| NO20071515L (no) | 2007-05-22 |
| EA011773B1 (ru) | 2009-06-30 |
| ZA200702364B (en) | 2008-09-25 |
| EP1799644A1 (en) | 2007-06-27 |
| TW200613275A (en) | 2006-05-01 |
| US7683179B2 (en) | 2010-03-23 |
| MX2007002141A (es) | 2007-04-27 |
| CA2575078A1 (en) | 2006-03-02 |
| PE20060629A1 (es) | 2006-08-11 |
| WO2006021397A1 (en) | 2006-03-02 |
| ES2462921T3 (es) | 2014-05-26 |
| AR050467A1 (es) | 2006-10-25 |
| CN101048379A (zh) | 2007-10-03 |
| BRPI0514606A (pt) | 2008-06-17 |
| US20060047125A1 (en) | 2006-03-02 |
| WO2006021397A8 (en) | 2006-04-27 |
| AU2005276619A1 (en) | 2006-03-02 |
| EP1799644B1 (en) | 2014-02-12 |
| JP2008510754A (ja) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ553127A (en) | L-lactic, saccharin, cinnamic, salicyclic, benzenesulphonic and naphthalene-1,5-disulphonic acid addition salts of lercanidipine | |
| US7482453B2 (en) | Process for the manufacture of (+)-(S)-clopidogrel bisulfate form-1 | |
| WO2001035957A8 (de) | Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen | |
| EP1690861A3 (en) | A process for preparing duloxetine and intermediates for use therein | |
| RU2002111333A (ru) | Способ получения производных 4''-замещенных 9-деоксо-9а-аза-9а-гомоэритромицина а | |
| BR0109048A (pt) | Processo para a sìntese de citalopram | |
| TNSN05140A1 (en) | Perindopril | |
| AU2003208552A1 (en) | Process for preparing a pharmaceutically active compound (granisetron) | |
| CA2438854A1 (en) | Method of preparing non-hydrated fexofenadine hydrochloride and novel crystalline form obtainable by this method | |
| CN115594613B (zh) | 依度沙班中间体及其制备方法 | |
| EP1327626A4 (en) | PRAVASTATIN PURIFICATION PROCESS | |
| RU2005109560A (ru) | Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина | |
| CA2671816A1 (en) | Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same | |
| WO2004108665A2 (en) | A process for preparation of clopidogrel | |
| CO5470281A1 (es) | Procedimiento de sintesis mejorado de derivados de acido naftiridin-3-carboxilico | |
| WO2007049295B1 (en) | An improved one pot process for making key intermediate for gemcitabine hcl | |
| WO1999015492A1 (en) | Method for preparing bicycloheptan-amine compounds | |
| US8080663B2 (en) | Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine | |
| KR101093866B1 (ko) | 티옥트산의 엘-카르니틴과의 염기성 염 | |
| WO2004099138A3 (en) | Process for the preparation of perindopril | |
| WO2005023769A1 (en) | Process for the preparation of amlodipine salts | |
| ITMI20102262A1 (it) | Procedimento per la preparazione di fesoterodina o un suo sale | |
| GB2418916A (en) | Process for purifying citalopram using polybasic acids | |
| DK1200436T3 (da) | Fremgangsmåde til fremstilling af rene stereoisomerer af tetrahydrofolsyreestersalte og tetrahydrofolsyre ved fraktioneret krystallisering af tetrahydrofolsyreestersalte | |
| WO2005107374A3 (en) | A process for the preparation of 1,4-dihydropyridine-3,5-dicarboxylic acid derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |